Trial Profile
Phase I trial of Thrombin-inhibitor VE-2851
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs VE-2851 (Primary)
- Indications Acute coronary syndromes; Stroke; Venous thrombosis
- Focus Adverse reactions
- 14 Dec 2022 According to a Verseon media release, trial is expected to initiate at a later date.
- 23 Nov 2017 New trial record
- 15 Nov 2017 According to a Verseon media release, this trial is expected to start in 2018